Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.67 |
| ▸ | HPGD | P15428 | 9/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 8/20 | 0.67 |
| ▸ | TP53 | P04637 | 7/20 | 0.67 |
| ▸ | MEN1 | O00255 | 7/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.67 |
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.67 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | MAOA | P21397 | 6/20 | 0.65 |
| ▸ | MAOB | P27338 | 6/20 | 0.65 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daidzein SCHEMBL4188877 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| Genistein SCHEMBL12488651 | 0.86 | MAPT (0.65) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| Genistein SCHEMBL554356 | 0.86 | SMN1; SMN2 (0.79) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| Apigenin SCHEMBL3430874 | 0.85 | CYP3A4 (0.78) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| Genistein SCHEMBL7563328 | 0.83 | SMN1; SMN2 (0.89) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| Kaempferol SCHEMBL28180527 | 0.82 | ABCB1 (0.69) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| SCHEMBL10623004 | 0.82 | SMN1; SMN2 (0.94) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| 5,7-Dihydroxyisoflavone SCHEMBL1586459 | 0.82 | MEN1 (1.00) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| Chrysin SCHEMBL3858957 | 0.81 | ABCB1 (0.84) | SMN1; SMN2HPGDCYP3A4MAPTTP53 | |
| Genistein SCHEMBL554056 | 0.81 | MAPT (1.00) | SMN1; SMN2HPGDCYP3A4MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10765732-B2 | Compounds and methods for affecting cytokines | Zivo Bioscience, Inc. (US) | 2020-09-08 | — | — | US | disclosed |
| US-20190175717-A1 | COMPOUNDS AND METHODS FOR AFFECTING CYTOKINES | Zivo Bioscience, Inc. (US) | 2019-06-13 | — | — | US | disclosed |
| US-10232028-B2 | Compounds and methods for affecting cytokines | Zivo Bioscience, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20160120970-A1 | COMPOUNDS AND METHODS FOR AFFECTING CYTOKINES | Zivo Bioscience, Inc. | 2016-05-05 | — | — | US | disclosed |
| US-9073863-B2 | Cyanoquinoline compounds having activity in correcting mutant-CFTR processing and increasing ion transport and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-07-07 | — | — | US | disclosed |
| WO-2014201372-A1 | COMPOUNDS AND METHODS FOR AFFECTING CYTOKINES | HEALTH ENHANCEMENT PRODUCTS, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-10-02 | — | — | US | disclosed |
| US-8389736-B2 | Compounds having activity in correcting mutant-CFTR processing and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-05 | — | — | US | disclosed |
| WO-2012166654-A1 | CYANOQUINOLINE COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND INCREASING ION TRANSPORT AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-12-06 | — | — | WO | disclosed |
| US-20120101143-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-CFTR and Uses Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-04-26 | — | — | US | disclosed |
| EP-1765347-A4 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | UNIV CALIFORNIA (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1863522-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20070265316-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-11-15 | — | — | US | disclosed |
| EP-1765347-A2 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | The Regents of the University of California (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006101740-A2 | COMPOUNDS HAVING ACTIVITY IN CORRECTING MUTANT-CFTR PROCESSING AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2005120497-A2 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-12-22 | — | — | WO | disclosed |
| US-6949558-B2 | Enhancement of taxane-based chemotherapy by a CDK1 antagonist | YALE UNIVERSITY (US) | 2005-09-27 | — | — | US | disclosed |
| WO-2004110352-A2 | COMPOUNDS HAVING ACTIVITY IN INCREASING ION TRANSPORT BY MUTANT-CFTR AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-12-23 | — | — | WO | disclosed |
| US-20030125374-A1 | Enhancement of taxane-based chemotherapy by a CDK1 antagonist | YALE UNIVERSITY | 2003-07-03 | — | — | US | disclosed |
| WO-2003039536-A1 | ENHANCEMENT OF TAXANE-BASED CHEMOTHERAPY BY A CDK1 ANTAGONIST | YALE UNIVERSITY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296215-A1 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof | CFTR, SLC47A1, SLC47A2 | SMN1; SMN2 2288/4885HPGD 2176/4885CYP3A4 2081/4885 |
| US-20070265316-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof | CFTR, SLC47A1, SLC47A2 | SMN1; SMN2 3371/4885HPGD 1277/4885CYP3A4 3178/4885 |
| US-20120101143-A1 | Compounds Having Activity in Increasing Ion Transport by Mutant-CFTR and Uses Thereof | CFTR, ABCC9, ABCB11 | SMN1; SMN2 3568/4885HPGD 1983/4885CYP3A4 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.